GlassScriptPhysician profile
Jennifer Rivas
NPI 1740676352
$2,350.26
in general payments reported to CMS, 2019-2025
15 companies · $1,918 in 2025
The $1,918 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.73 · 2024: $417 · 2025: $1,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,250 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,249.54 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $657.50 | 2024-2025 | |
| Janssen Biotech, INC. | $376.09 | 2025 | Tremfya, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $357.20 | 2024-2025 | Xifaxan |
| Ardelyx, INC. | $321.26 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $169.13 | 2025 | Sucraid |
| Aimmune Therapeutics, INC. | $115.93 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $85.99 | 2024-2025 | Dupixent |
| Gilead Sciences, INC. | $71.51 | 2025 | |
| Phathom Pharmaceuticals, INC. | $62.23 | 2024-2025 | Voquezna |
| Genzyme Corporation | $30.45 | 2025 | |
| Ironwood Pharmaceuticals, INC | $24.53 | 2024 | |
| Lilly USA, LLC | $23.17 | 2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $23.01 | 2024 | Rebyota |
| Pfizer INC. | $16.53 | 2025 | |
| Boston Scientific Corporation | $15.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Rivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.